Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Orbimed Advisors Takes a Major Stake in Ambit Biosciences Corp (AMBI)

In the smart money’s world, Samuel Isaly’s Orbimed Advisors reported a purchase of some 2.1 million shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a 13D filing with the SEC’s Edgar system. In total, at the current price of company’s shares, the value of the holding in Ambit Biosciences Corp (NASDAQ:AMBI) is now worth close to $14.42 million. This is a new position in Orbimed Advisors’s equity portfolio.

On the whole, 13Ds indicate the intentions of activist hedge fund managers. These members of the smart money are the proverbialcelebrities in the financial space, and seek to take a brush stroke to an already standing business model.

To put it simply, it’s very beneficial for everyday investors to internalize Samuel Isaly’s latest trade into Ambit Biosciences Corp (NASDAQ:AMBI).

Though the media, analysts and the blogosphere at large reports on a multitude of equity-based metrics, there is one that stands out: consensus sentiment of the world’s best money managers.

At Insider Monkey, our research has demonstrated that retail investors who copy specific hedge fund activity can outperform the market by as much as 18 percentage points per year. (See the details here).

Keying on Ambit Biosciences Corp (NASDAQ:AMBI), we should mention that the company has recently announced its Initial Publig Offering. According to a statement on the company’s website, the IPO involved about 8.2 million shares at a price of $8 apiece.

Moreover, we should mention some other stocks in Orbimed Advisors’s equity portfolio, in addition to Ambit Biosciences Corp (NASDAQ:AMBI).

As follows, they include Pfizer Inc. (NYSE:PFE), Biogen Idec Inc. (NASDAQ:BIIB), Merck & Co., Inc. (NYSE:MRK) and are discussed on the following page: